PDI 2009 ISDP LAC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 27(4): 424-431 2007
© 2007 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ersoy, R.
Right arrow Articles by Camsari, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ersoy, R.
Right arrow Articles by Camsari, T.

Bench Science

THE EFFECTS OF IRBESARTAN AND SPIRONOLACTONE IN PREVENTION OF PERITONEAL FIBROSIS IN RATS

Rifki Ersoy1, Ali Celik1, Osman Yilmaz2, Sulen Sarioglu3, Banu Sis3, Pinar Akan4, Yavuz Yenicerioglu1, Murat Ormen4 and Taner Camsari1

Departments of 1 Nephrology,2 Animal Laboratory,3 Pathology, 4 and Biochemistry, Dokuz Eylül University Medical School, Izmir, Turkey

Correspondence to: R. Ersoy, Department of Nephrology, Dokuz Eylül University Medical School, 155. sok. No. 43/10 Hatay, Izmir, Turkey.
uzmanersoy{at}yahoo.com

{diamondsuit} Background: Bacterial peritonitis episodes may disturb the functional and histological integrity of the peritoneum in peritoneal dialysis patients. The renin-angiotensin-aldosterone system may have fibrotic effects on the peritoneum.

{diamondsuit} Objective: To study the effects of an angiotensin II receptor antagonist (irbesartan) and an aldosterone antagonist (spironolactone) in the prevention of peritoneal fibrosis in a rat model of bacterial peritonitis.

{diamondsuit} Methods: 40 Wistar rats were randomized into 5 groups: bacteria (B), bacteria-irbesartan (BI), bacteria-spironolactone (BS), bacteria-irbesartan-spironolactone (BIS), and control (C) groups. The C group received only dextran beads (Cytodex; Sigma Chemicals, St Louis, Missouri, USA); the others were given bacteria and dextran beads intraperitoneally. Irbesartan and/or spironolactone were given to 3 groups: BI, BS, and BIS. On the eighth day, the rats were sacrificed, peritoneal adhesion was quantified, and peritoneal tissue sections were evaluated histologically.

{diamondsuit} Results: The peritoneal total adhesion score was significantly higher in the B group than in the BI, BIS, and C groups (p < 0.01). Mean peritoneal thickness, mean inflammation score, and mean fibrosis score were significantly higher in the B group in comparison to the C group (p < 0.05). Mean peritoneal thickness of all treatment groups was significantly lower than the B group (p < 0.05). Serum transforming growth factor beta-1 level was significantly higher in the B group than in the BI, BS, and C groups (p < 0.05).

{diamondsuit} Conclusion: Irbesartan and spironolactone seem to decrease the extent of peritoneal injury caused by bacterial peritonitis.

KEY WORDS: Peritonitis; peritoneal fibrosis; irbesartan; spironolactone; TGF-ß1.

Received 7 March 2006; accepted 20 March 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2007 by Multimed Inc.